Anti-allergic agent – H1-histamine receptor blocker.
ATX code [R06AX27]
Pharmacological properties
Indications
Conjunctivitis, Skin itching, Dermatitis, Increased lacrimation, Runny nose, Sneezing, Pollinosis, Edema, Urticaria, Allergies, Nasal congestion
- Allergic rhinitis (elimination or relief of nasal mucus and itching of the palate, itching and red eyesAllergic rhinitis (elimination or relief of sneezing, nasal congestion, nasal mucus discharge, nasal itching, palate itching, itching and red eyes, lacrimation);
- Mottling (reduction or elimination of skin itching, rash).
.
Active ingredient
Desloratadine
Composition
1 tablet contains:
How to take, the dosage
Orally, regardless of meals. It is necessary to open the blister carefully and take out the tablet without breaking it. The tablet for dissolution is placed on the tongue, where it dissolves, and then it is swallowed with saliva without drinking water or other liquids. The tablet should be taken immediately after opening the blister.
Adults and teenagers over 12 years old: 1 tablet for dissolution (5 mg) 1 time per day for reduction of symptoms of allergic rhinitis (including seasonal and year-round allergic rhinitis) and urticaria.
In seasonal (intermittent) allergic rhinitis (with symptoms lasting less than 4 days per week or less than 4 weeks per year) the course of the disease should be evaluated. In case of symptoms disappearance the drug shall be stopped, in case of recurrent symptoms the drug administration shall be renewed.
In case of year-round (persistent) allergic rhinitis (in the presence of symptoms lasting for more than 4 days a week or more than 4 weeks a year) the drug shall be taken during the whole period of allergen exposure.
Interaction
In multiple co-administration of desloratadine with ketoconazole, erythromycin, azithromycin, fluoxetine and cimetidine no clinically significant changes in plasma concentrations of desloratadine were found. BLOGIR-3® does not increase the effect of alcohol on the central nervous system. Food intake has no effect on the effectiveness of the drug.
.
Special Instructions
With caution desloratadine is prescribed in severe renal failure.
Influence on driving and operating machinery
There have been no adverse effects on driving or operating complex technical devices.
Contraindications
hypersensitivity to desloratadine, other drug components or loratadine;
phenylketonuria;
pregnancy;
breastfeeding period;
under 12 years of age.
With caution: severe renal insufficiency; seizures in anamnesis.
Side effects
The frequency of adverse reactions is classified according to the recommendations of the World Health Organization: very common – at least 10%; common – at least 1%, but less than 10%; infrequent – at least 0.1%, but less than 1%; rare – at least 0.01%, but less than 0.1%; very rare – less than 0.01%, including individual reports.
The most common adverse effects (>1/100 to <1/10): fatigue, dry mouth, and headache.
Very rarely (<1/10,000) the following unwanted effects were noted:
Central nervous system: hallucinations, dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures.
Cardiovascular system: tachycardia, palpitations.
Digestive system: abdominal pain, nausea, vomiting, dyspepsia, diarrhea.
Liver and biliary tract: increased liver transaminase activity, increased concentration of bilirubin, hepatitis.
Musculoskeletal system: myalgia.
Immune system: anaphylaxis, angioneurotic edema, dyspnea, itching, rash, including urticaria, photosensitization.
If any of the side effects specified in the instructions are aggravated, or if you notice any other side effects not specified in the instructions, inform the doctor.
Overdose
In clinical trials when using desloratadine in doses up to 45 mg (9 times the therapeutic dose) no clinically significant adverse effects were observed.
Treatment: In case of overdose standard measures are taken to remove the active substance from the gastrointestinal tract. Symptomatic and supportive therapy is recommended.
Desloratadine is not excreted by hemodialysis, the effectiveness of peritoneal dialysis has not been established.
Pregnancy use
The use of the drug BLOGIR-3® during pregnancy is contraindicated due to the lack of clinical data on the safety of its use during this period.
Desloratadine is excreted with the breast milk, so the use of the drug during breast-feeding is contraindicated.
Similarities
Lordestin, Erius, Dezal, Desloratadine, BLOGIR-3, Ezlor
Weight | 0.025 kg |
---|---|
Shelf life | 3 years. Do not use after the expiration date. |
Conditions of storage | At a temperature not exceeding 25 °C. Keep out of reach of children! |
Manufacturer | Genepharm S.A., Greece |
Medication form | lozenges |
Brand | Genepharm S.A. |
Other forms…
Related products
Buy BLOGIR-3, tablets 5 mg 30 pcs with delivery to USA, UK, Europe and over 120 other countries.